Korsana Biosciences, Inc., a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, has emerged from stealth, with backing from healthcare investors.
The company was founded in 2024 with a $25m seed investment from Fairmount and Venrock Healthcare Capital Partners. In September 2025, the company closed a $150m private Series A financing co-led by Wellington Management and TCGX, with participation by J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital, and others. The funding is being used to develop potential best-in-class therapeutics to treat neurodegenerative diseases, with an initial focus on Alzheimer’s disease.
Korsana’s lead programme is KRSA-028, a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease, discovered in partnership with Paragon Therapeutics. KRSA-028 utilises the proprietary Therapeutic Targeting (THETA) platform, which incorporates clinically validated transferrin receptor (TfR1) and Fc engineering and is designed to improve brain delivery and solve limitations of other TfR1-based approaches. KRSA-028 was designed to increase amyloid plaque clearance, reduce the rate of amyloid-related imaging abnormalities (ARIA) and hematologic adverse events, and optimize convenience and compliance with a low-volume subcutaneous route of administration. Korsana is advancing a pipeline of innovative THETA-enabled therapies for other undisclosed, neurodegenerative diseases with high unmet need.
Korsana has appointed Jonathan Violin as president and chief executive officer. Violin has been a venture partner at Fairmount since 2023 and previously served as founding CEO for Viridian Therapeutics from 2020 to 2023. He was also the founding CEO of Dianthus Therapeutics and of Quellis Biosciences, which merged into Astria Therapeutics.
“We are thrilled to announce the launch of Korsana with a mission to elevate expectations for patients suffering from devastating neurodegenerative diseases,” Violin said.
“In particular, Alzheimer’s disease represents a massive and growing unmet need, with the US patient population projected to double to approximately 13m by 2050. Only two disease-modifying therapies have been approved to treat Alzheimer’s, and both carry safety warnings, offer only modest efficacy, and impose a high burden of care. Patients deserve better options than what is currently available, and we believe our lead program KRSA-028 can deliver a best-in-class product to treat Alzheimer’s. I am thrilled with the robust support of our mission by Korsana’s investors, and excited to build another leading biotechnology company in partnership with the team at Paragon Therapeutics.”
Korsana’s initial financing is expected to fund activities into 2028 and provides runway through key clinical milestones, which include potentially differentiating pharmacokinetics, CNS penetration, and safety data from healthy volunteers expected in mid-year 2027, and initial proof of concept data demonstrating amyloid plaque clearance in Alzheimer’s patients expected by the end of 2027.